Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards;Estudio farmacogenético del polimorfismo metabólico de la debrisoquina (CYP2D6) en la población cubana en relación con la española

Medicina Clinica

Volumn 128, Issue 20, 2007, Pages 772-774

  González, Idilio ^a,c   Pérez, Bárbaro ^b   Álvarez, Mayra ^b   Dorado, Pedro ^c   Llerena, Adrián ^c  

^a HOSPITAL PSIQUIÁTRICO DE LA HABANA   (Cuba)

^b Facultad de Ciencias Medicas General Calixto Garcia   (Cuba)

^c UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Cubans; CYP2D6; Debrisoquine; Hispanics; Interethnic variability; Pharmacogenetics; Phenotype; Spaniards

Indexed keywords

CYTOCHROME P450 2D6; DEBRISOQUINE;

ADULT; ARTICLE; CONTROLLED STUDY; CUBA; DRUG METABOLISM; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; PHENOTYPE; SPAIN;

EID: 34347370196     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13106328     Document Type: Article

References (10)

1. Llerena A, Cobaleda J, Martínez C, Benítez J. Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet. 1996;21:129-38.
2. Meadows M. FDA approves heart drug for black patients. FDA Consum. 2005;39:8-9.
3. Álvarez MC, Pérez BH, Llerena A, Labacena MR, García LB, Rojo DH. Estudio del polimorfismo de debrisoquina en una muestra de ia población cubana. Rev Cubana Farm. 2005;39:1-3.
4. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine relation capacity. Suggestions for an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand. 1993;87:23-8.
5. Dorado P, Berecz R, Cáceres MC, González I, Cobaleda J, Llerena A. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin Chem Lab Med. 2005;43:275-9.
6. González I, Cáceres M, Llerena A, Berecz R, Kiivet R. Estudio de utilización de antipsicóticos en la esquizofrenia en hospitales de España, Estonia, Hungrĩa y Cuba. Rev Hosp Psiquiatr La Habana [revista electrónical. 2004; 1(2). Disponible en: http://www.psiquiatricohph.sld.cu/hph0204/hphsu0204.htm
7. Llerena A, Berecz R, Dorado P, De la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004;18:189-93.
8. Llerena A, Berecz R, De la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002,16:361-4.
9. Llerena A, Berecz R, De la Rubia A, Dorado P. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. Eur J Clin Pharmacol. 2002;58:223-4.
10. Vincent-Viry M, Fournier B, Galteau MM. The effects of drinking and smoking on the CYP2D6 metabolic capacity. Drug Metab Dispos. 2000;28:617-9.